• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Upadacitinib significantly improves clinical remission rate for moderately to severely active ulcerative colitis

byJessie WillisandTeddy Guo
June 14, 2022
in Chronic Disease, Gastroenterology, Rheumatology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Upadacitinib led to significantly greater percentages of clinical remission compared to placebo for both induction and maintenance studies.

2. Treatment discontinuation due to serious adverse events was more frequent among the placebo group than those receiving upadacitinib.

Evidence Rating Level: 1 (Excellent)

Study Rundown: This study reported a summary of findings from two induction studies and one maintenance study (U-ACHIEVE, U-ACCOMPLISH, and U-CHIEVE maintenance) of oral daily upadacitinib for moderate to severe ulcerative colitis. Patients were randomized to receive either placebo or upadacitinib for 8 weeks in the induction studies. If clinical improvement was achieved, participants were re-randomized to receive either placebo, 15 mg, or 30 mg upadacitinib for 52 weeks in the maintenance study. Clinical remission was monitored with the Adapted Mayo score. Results from the induction study demonstrate a statistically significant increase in clinical remission among the treatment group compared to placebo. Similarly, clinical remission at 52-weeks favored the upadacitinib group compared to placebo. The most common adverse events in the treatment group were nasopharyngitis, creatinine phosphokinase elevation, and acne in the induction study. However, in both induction and maintenance studies, there were less serious adverse events leading to discontinuation in the treatment group compared to placebo. Limitations of this study include lack of long-term follow-up past one year. Nevertheless, this study provides a potential treatment option for ulcerative colitis.

Click to read the study in The Lancet

Relevant Reading: Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

In-Depth [randomized control trial]: This study is secondary to two replicate induction studies and a maintenance study. Eligible patients were aged 16-75 years with moderately to severely active ulcerative colitis. In the two induction studies, 474 and 522 patients were randomly assigned 2:1 to oral upadacitinib once daily or placebo for 8 weeks. After 8 weeks, if clinical response was achieved, patients (n=451) were randomly reassigned 1:1:1 to upadacitinib 15 mg, 30 mg or placebo for 52 weeks. Clinical remission was assessed using the Adapted Mayo score. Clinical remission was achieved in a greater percentage of patients with upadacitinib 45 mg (26% and 34%) compared to placebo (5% and 4%; p<0.0001) during the induction phase. Similarly, for the maintenance study, statistically greater percentage of clinical remission was achieved in the upadacitinib 30 mg group compared to placebo (52% vs. 12%, p<0.0001). The most common adverse events were nasopharyngitis, creatine phosphokinase elevation, and acne in the induction study. There were less serious adverse events in the treatment group compared to placebo in both the induction and maintenance study.

RELATED REPORTS

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

Early-life body size not an independent risk factor for colorectal cancer

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Crohn's DiseaseGastroenterologyinflammatory bowel diseaseJAK1 inhibitorUlcerative Colitisupadacitinib
Previous Post

Obsessive-compulsive disorder and obsessive-compulsive symptoms associated with an elevated risk of substance misuse

Next Post

High intensity interval training improves fitness in children and adolescents

RelatedReports

Resection of colorectal liver metastases may improve cost and longevity
Chronic Disease

Epstein-Barr viral load monitoring reduces risk of post-liver transplant lymphoproliferative disease

January 30, 2023
Long-term use of apremilast for psoriasis associated with an acceptable safety profile
Chronic Disease

Bimekizumab is effective for active psoriatic arthritis in biologic-naĂŻve adults

January 24, 2023
Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Early-life body size not an independent risk factor for colorectal cancer

January 11, 2023
Extensive lymphadenectomy may not increase patient survival with esophageal cancer
Chronic Disease

Dupilumab improves symptoms and increases remission rates in eosinophilic esophagitis

January 9, 2023
Next Post
Adolescent mothers in protective care more likely to have their children placed in care

High intensity interval training improves fitness in children and adolescents

#VisualAbstract: Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

#VisualAbstract: Perioperative dexmedetomidine decreases the incidence of select complications following kidney transplantation

Increasing C-section room temperature linked to reduced neonatal, maternal hypothermia

Global mortality of neonates born preterm has decreased nearly 50 percent since 1990

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options